Please try another search
For the fiscal year ended 31 December 2021, Bioretec Oy revenues increased 34% to EUR2M. Net loss increased from EUR2.3M to EUR6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Financial Expense - Total increase from EUR347K to EUR3.4M (expense), Other Operating Expense increase of 52% to EUR1.7M (expense).
Period Ending: | Dec 31, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
---|---|---|---|---|
Total Revenue | 0.96 | 1.05 | 0.52 | 0.77 |
Gross Profit | 0.6 | 0.78 | 0.41 | 0.55 |
Operating Income | -1.44 | -1.23 | -0.54 | -0.89 |
Net Income | -3.23 | -2.79 | -0.54 | -0.89 |
Period Ending: | Dec 31, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
---|---|---|---|---|
Total Assets | 8.58 | 10.18 | 3.74 | 3.89 |
Total Liabilities | 4.24 | 4.36 | 2.87 | 2.53 |
Total Equity | 4.34 | 5.82 | 0.87 | 1.36 |
Period Ending: | Dec 31, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
---|---|---|---|---|
Period Length: | 12 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -2.39 | -1.24 | -0.59 | -2 |
Cash From Investing Activities | -0.39 | -0.14 | -0.09 | -0.12 |
Cash From Financing Activities | 7.13 | -0.03 | 0.04 | 4.33 |
Net Change in Cash | 4.35 | -1.41 | -0.64 | 2.22 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review